IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

Springer London

Abstract

This committee opinion reviews the laser-based vaginal devices for treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The United States Food and Drug Administration has issued a warning for unsubstantiated advertising and use of energy-based devices. Well-designed case–control studies are required to further investigate the potential benefits, harm, and efficacy of laser therapy in the treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The therapeutic advantages of nonsurgical laser-based devices in urogynecology can only be recommended after robust clinical trials have demonstrated their long-term complication profile, safety, and efficacy. © 2018, The International Urogynecological Association.

Description

Keywords

Energy-based devices, Fda, Genitourinary syndrome of menopause, Laser, Stress urinary incontinence, Vaginal laxity, Atrophy, Female, Humans, Lasers, solid-state, Low-level light therapy, Menopause, Syndrome, Urinary incontinence, stress, Vagina, Vaginal diseases, Vulva, Clinical trial (topic), Human, Low level laser therapy, Menopause related disorder, Patient safety, Priority journal, Review, Sexual function, Stress incontinence, Therapy effect, Vagina disease, Adverse device effect, Adverse event, Drug therapy, Pathology, Solid state laser

Citation

Endorsement

Review

Supplemented By

Referenced By